RecruitingNot ApplicableNCT06036446

LATe Cerclage in High-risk Pregnancies (LATCH)

Cervical Cerclage for Short Cervix at 24-26 Weeks of Gestation: a Randomized Controlled Trial


Sponsor

Thomas Jefferson University

Enrollment

329 participants

Start Date

Nov 10, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to determine whether cervical cerclage reduces the risk of preterm birth in patients with a short transvaginal ultrasound (TVU) cervical length (CL) ≤25mm between 24 0/7-26 6/7 weeks.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Cervical cerclage and a drug called Vaginal Suppository Progesterone for people with premature birth. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURECervical cerclage

Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.

DRUGVaginal Suppository Progesterone

Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.


Locations(2)

Atrium Health Carolinas Medical Center

Charlotte, North Carolina, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06036446


Related Trials